Added to YB: 2025-12-13
Pitch date: 2025-12-11
MEDCL.PA [bullish]
MedinCell S.A.
-9.22%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France.
Market Cap
EUR 910.1M
Pitch Price
EUR 29.50
Price Target
N/A
Dividend
N/A
EV/EBITDA
-96.53
P/E
-44.20
EV/Sales
32.66
Sector
Pharmaceuticals
Category
growth
Medincell (MEDCL France): execution on track as UZEDY gains traction and pipeline advances
MEDCL.PA (update): LAI platform gaining traction with UZEDY royalties driving 35% revenue growth to €11.6M. Teva expects $190-200M UZEDY sales 2025, olanzapine FDA submission accepted for 10-month review. Strong phase III safety data, no post-injection issues. €53.5M cash runway through milestones.
Read full article (2 min)